Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deoxycytidine/deoxythymidine - Modis Therapeutics

Next Previous
Drug Profile

Deoxycytidine/deoxythymidine - Modis Therapeutics

Alternative Names: dC/dT - Modis Therapeutics; Deoxycytidine/deoxythymidine; doxTM; MT 1621 - UCB; MT-1621; Thymidine/deoxycytidine - Modis Therapeutics

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University Medical Center; Vall d-Hebron Research Institute
  • Developer Columbia University Medical Center; Modis Therapeutics; Vall d-Hebron Research Institute
  • Class Deoxyribonucleosides; Small molecules
  • Mechanism of Action Deoxyribonucleoside replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Mitochondrial disorders

Most Recent Events

  • 04 Aug 2023 Chemical structure information added
  • 12 Dec 2022 Phase-III clinical trials in Mitochondrial disorders (In adolescents, In children, In the elderly, In adults) in USA (PO) (Modis Therapeutics pipeline; December 2022)
  • 22 Jul 2022 Modis Therapeutics withdraws a phase III trial prior to enrolment for Mitochondrial disorders (Treatment-naive, In adolescents, In children, In infants, In neonates) in US in July 2022 (NCT04581733)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top